RFA-AI-28-004-Revised-Full-Announcement.html

HTML file 168 KB Posted

Attached to
HIV/AIDS Clinical Trials Network Clinical Trials Units (UM1 Clinical Trial Required)
Opportunity number
RFA-AI-28-004
Issued by

About this file

This is a Notice of Funding Opportunity (NOFO) for HIV/AIDS Clinical Trials Network Clinical Trials Units (CTUs) under the UM1 cooperative agreement mechanism. The National Institute of Allergy and Infectious Diseases (NIAID) and nine partner NIH institutes seek to establish CTUs providing infrastructure and scientific expertise to conduct HIV clinical studies across four networks: HIV/AIDS Adult Therapeutics, HIV/AIDS Maternal/Adolescent/Pediatric, HIV Prevention, and Immune-Based Prevention. Each CTU comprises an administrative hub and 1-8 domestic and/or international Clinical Research Sites (CRSs) with integrated pharmacy and laboratory support. NIAID will commit an estimated $60 million to fund 45-65 awards in FY2028. Applications are due by 5:00 PM local time on the posted application due date, with an open date of February 9, 2027, and earliest start date of March 9, 2027. The project period is 7 years, with awards structured as incrementally funded cooperative agreements requiring annual progress and financial reporting. Awards are not limited in budget but must reflect actual project needs based on CTU scope. Funding consists of core funds for infrastructure and administrative support, plus protocol funds allocated annually based on network needs.

Eligible applicants include higher education institutions, nonprofits with and without 501(c)(3) status, for-profit organizations, government entities, tribal governments, faith-based organizations, and foreign institutions; however, NIH will not issue awards involving foreign subawards or subcontracts. Applicants must register with System for Award Management (SAM), obtain a Unique Entity Identifier, complete eRA Commons registration, and register with Grants.gov before submission. The application requires detailed organizational charts, staffing plans demonstrating complex clinical trial management experience, administrative and financial management strategies, communication protocols, evaluation and performance metrics, compliance and regulatory procedures, and community engagement plans. For each proposed CRS, applicants must document staffing, previous IND-level trial experience, quality management structures, training programs, IRB/regulatory processes, implementation science capacity, pharmacy operations, laboratory capabilities, and data stewardship infrastructure. All applications must propose clinical trials and include a Delayed Onset Study record with anticipated clinical trial designation, as specific protocols will be developed during the project period through Network approval processes.

RFA-AI-28-004-Revised-Full-Announcement.html

Text of this file

Department of Health and Human Services

Part 1. Overview Information

Participating Organization(s)

National Institutes of Health (NIH)

Components of Participating Organizations

National Institute of Allergy and Infectious Diseases (NIAID)

Office of AIDS Research (OAR)

National Heart, Lung, and Blood Institute (NHLBI)

National Institute on Aging (NIA)

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

National Institute of Dental and Craniofacial Research (NIDCR)

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

National Institute on Drug Abuse (NIDA)

National Institute of Mental Health (NIMH)

National Institute of Neurological Disorders and Stroke (NINDS)

Applicants should carefully note which ICOs participate in this announcement and refer to NIH Institute, Center, and Office Grants & Funding Profiles for ICO-specific missions, interest areas, priorities, and funding considerations.

Funding Opportunity Title

HIV/AIDS Clinical Trials Network Clinical Trials Units (UM1 Clinical Trial Required)

Activity Code

UM1 Research Project with Complex Structure Cooperative Agreement

Announcement Type

Reissue of

RFA-AI-19-045

Related Notices

Check for any recent Notices of NIH Policy Changes that may impact application requirements.

Funding Opportunity Number (FON)

RFA-AI-28-004

Companion Funding Opportunity

RFA-AI-28-001

, UM1

Research Project with Complex Structure Cooperative Agreement

RFA-AI-28-002

RFA-AI-28-003

Number of Applications

See Part 2, Section III. 3. Additional Information on Eligibility.

Assistance Listing Number(s)

93.8RP, 93.HDR, 93.AGR, 93.310, 93.853, 93.242, 93.HL2, 93.DA1, 93.KRP, 93.DE1

Funding Opportunity Purpose

The purpose of this notice of funding opportunity (NOFO) is to support HIV/AIDS Clinical Trials Network Clinical Trials Units (CTUs). CTUs will provide the infrastructure, as well as the scientific and administrative expertise to conduct clinical studies developed by NIH HIV/AIDS Clinical Trials Networks to advance research in the prevention and treatment of HIV and HIV-associated diseases. CTUs will participate in multiple clinical research studies, accessing relevant populations most heavily impacted by the HIV/AIDS epidemic and studies of highest priority to NIH.

Funding Opportunity Goal(s)

NIH's mission is to seek fundamental knowledge about the nature and behavior of living systems and the application of that knowledge to enhance health, lengthen life, and reduce illness and disability.

Key Dates

Posted Date

November 20, 2026

Open Date (Earliest Submission Date)

February 09, 2027

Application Due Dates
Review and Award Cycles
New
Renewal / Resubmission / Revision (as allowed)

AIDS - New/Renewal/Resubmission/Revision, as allowed

Scientific Merit Review
Advisory Council Review
Earliest Start Date

March 09, 2027

March 09, 2027

Not Applicable

July 2027
October 2027

December 2027

All applications are due by 5:00 PM local time of applicant organization.

Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Expiration Date

March 10, 2027

Due Dates for E.O. 12372

Not Applicable

Required Application Instructions

It is critical that applicants follow the instructions in the Research (R) Instructions in the How to Apply - Application Guide, except where instructed to do otherwise (in this NOFO or in a Notice from NIH Guide for Grants and Contracts).

Conformance to all requirements (both in the How to Apply - Application Guide and the NOFO) is required and strictly enforced. Applicants must read and follow all application instructions in the How to Apply - Application Guide as well as any program-specific instructions noted in Section IV. When the program-specific instructions deviate from those in the How to Apply - Application Guide, follow the program-specific instructions.

Applications that do not comply with these instructions may be delayed or not accepted for review.

There are several options available to submit your application through Grants.gov to NIH and Department of Health and Human Services partners. You must use one of these submission options to access the application forms for this opportunity.
Use the NIH ASSIST system to prepare, submit and track your application online.
Use an institutional system-to-system (S2S) solution to prepare and submit your application to Grants.gov and eRA Commons to track your application. Check with your institutional officials regarding availability.
Use Grants.gov Workspace to prepare and submit your application and eRA Commons to track your application.

Table of Contents

Part 1. Overview Information Key Dates Part 2. Full Text of Announcement Section I. Notice of Funding Opportunity Description Section II. Award Information Section III. Eligibility Information Section IV. Application and Submission Information Section V. Application Review Information Section VI. Award Administration Information Section VII. Agency Contacts Section VIII. Other Information

Part 2. Full Text of Announcement

Section I. Notice of Funding Opportunity Description

Network Scope and Structure The National Institute of Allergy and Infectious Diseases (NIAID) and its Institute, Center and Office (ICO) partners will support four clinical trials networks with unique research agendas that will conduct HIV/AIDS prevention, treatment and implementation science research improving uptake of evidence-based strategies across the lifespan:

HIV/AIDS Adult Therapeutics Clinical Trials Network
HIV/AIDS Maternal, Adolescent and Pediatric Clinical Trials Network
HIV Prevention Clinical Trials Network
Immune-Based Prevention Clinical Trials Network

Each HIV/AIDS Clinical Trial Network is composed collectively of the following clinical trial infrastructure designed to support a complex clinical research agenda:

RFA-AI-28-001 - HIV/AIDS Clinical Trials Network Leadership and Operations Centers (LOCs) RFA-AI-28-002 - HIV/AIDS Clinical Trials Network Laboratory Centers (LCs) RFA-AI-28-003 - HIV/AIDS Clinical Trials Network Statistical and Data Management Centers (SDMCs) RFA-AI-28-004 - HIV/AIDS Clinical Trials Network Clinical Trials Units (CTUs) – this notice of funding opportunity (NOFO) While the emphasis of each Network is on clinical trials, clinical research studies that are not NIH-defined clinical trials are also in scope when undertaken to support the program. For this NOFO, the term "clinical study" refers to both clinical trials and clinical research studies, and "clinical trial" is used to refer to a clinical trial only.

Each Clinical Trials Network will have an Executive Management Committee (EMC), established by the LOC, to coordinate the activities of the Network's LOC, LC and SDMC.

NIAID is responsible for the oversight and safety of all study participants in clinical trials funded by NIAID and will provide NIAID-convened Data and Safety Monitoring Boards (DSMBs) to monitor clinical trials. NIAID will provide additional support services for Network trials under an Investigational New Drug (IND) or Investigational Device Exemption (IDE).

Clinical Trials Unit Overview The Clinical Trials Units (CTUs) are a core element of the HIV/AIDS Clinical Trials Networks that are structured to be an integrated unit with the demonstrated capacity to coordinate and execute clinical trials. CTUs are comprised of up to eight Clinical Research Sites (CRSs) supported by CRS pharmacy(ies) and CRS laboratory(ies). CRSs are discrete locations (e.g., hospital, clinics, community health centers, local health department clinics, etc.) with appropriate, identified and characterized potential trial participants where participant recruitment and retention, protocol management and other clinical research activities are conducted. Additional Protocol-Specific (PS) Clinical Research Sites may be added during the project period to rapidly address emerging Clinical Trial Network clinical research protocol needs and other NIH priorities.

CTUs employ robust regulatory assurance, data management, training, and quality management procedures and have demonstrated experience and/or capacity to support implementation science research. Each CTU provides scientific leadership, operational oversight, and infrastructure to support one or more HIV/AIDS Clinical Trials Networks. It functions as a cohesive, integrated unit with the capacity to conduct a broad range of clinical studies, in compliance with all applicable domestic and international regulations. International sites can offer opportunities for benefit to Americans living with, or at risk for acquiring, HIV and other HIV-associated infections when the proposed research cannot be accomplished as effectively or efficiently through domestic sites alone.

The Research Agendas for the four Networks are as follows:

1. HIV/AIDS Adult Therapeutics Clinical Trials Network – Responsible for supporting the advancement of therapeutics research toward the treatment and cure of adults living with HIV including implementation science and clinical research to improve the management of HIV-related co-morbidities, coinfections and aging. Key aspects to this research agenda include:

Implementation Science - strategies to adapt, deliver, and expand the reach, scale-up, and sustainability of evidence-based treatment for HIV and HIV-associated diseases.
Novel and Durable Interventions for HIV – strategies to achieve durable HIV suppression and improve treatment outcomes for adults living with HIV.
Anti-retroviral (ART)-Free Remission (HIV Cure) - strategies to eradicate HIV or sustain virologic remission through immune-based interventions.
Complications and Non-Infectious Comorbidities – strategies to improve the prevention, treatment and management of high-impact co-morbidities in PWH (e.g., neurocognitive, substance use disorders, cardiovascular diseases, lung diseases, diabetic and related metabolic and endocrine conditions, kidney, urologic and hematologic disease, oropharyngeal complications, aging associated conditions).
Viral Hepatitis - novel treatment strategies for hepatitis B virus (HBV) and hepatitis C virus (HCV) infection.
Tuberculosis - novel therapeutics and combination treatments for drug-sensitive and -resistant tuberculosis (TB).

Additionally, this Network will be responsible for the clinical research infrastructure to support early-stage pilot trials of novel products and approaches; opportunities for intensive sampling of potential tissue reservoirs of HIV; and specialized laboratory capabilities for virologic and immunologic analyses.

2. HIV/AIDS Maternal, Adolescent, and Pediatric Clinical Trials Network – Responsible for advancing research to generate the evidence base on novel, innovative therapies, interventions, methods, and strategic approaches for HIV and HIV-associated conditions in infants, children, adolescents, and pregnant/postpartum women, integrating implementation science across the product development lifecycle to speed their adoption and scale-up. Key aspects to this research agenda include:

Implementation Science - strategies to adapt, deliver and scale evidence-based interventions that optimize prevention for pregnant and breastfeeding women, strengthen maternal antiretroviral therapy (ART), tailor infant prophylaxis, and expand early and repeat HIV testing for breastfeeding infants and children.
HIV Treatment and Prevention Innovations - antiretroviral drug and regimen innovations in appropriate long-acting (or pediatric-friendly oral) formulations for pediatric and maternal populations and infant postnatal prophylaxis.
ART-Free Remission (HIV Cure) - strategies to achieve sustained virologic remission in pediatric populations, including strategies initiated in the immediate newborn period.
Treatment and Prevention of Tuberculosis and Other HIV-associated Co-Infections - new drugs and regimens for treatment and prevention of drug-sensitive and resistant TB disease, both pulmonary and extrapulmonary (including central nervous system [CNS]); address treatment needs for congenital syphilis, viral hepatitis (B and C), and other important HIV-associated co-occurring infections.
Brain and Mental Health and Other HIV-associated Comorbidities - Neuroprotective and neurotoxic effects of ART to preserve neurocognitive development and mental health in infants, children, and adolescents. Evaluate novel preventive and therapeutic approaches for other high-priority diseases and co-occurring conditions

3. HIV Prevention Clinical Trials Network – Responsible for advancing products and strategies to meet the needs of populations vulnerable to HIV acquisition including adults, adolescents and pregnant women, through the integration of biomedical, socio-behavioral and structural prevention strategies, in partnership with implementing agencies and organizations. Key aspects to this research agenda include:

Implementation Science – strategies to optimize deployment of and improve access to biomedical and socio-behavioral evidence-based interventions for HIV prevention.
Integrated Prevention Strategies - integration of socio-behavioral research to optimize HIV prevention outcomes tailored to the population and context, to improve HIV treatment uptake and adherence, retention in care, and reduction of HIV risk.
Novel Biomedical HIV Prevention and Delivery Systems - strategies and delivery methods that meet the needs of varied populations and help address the challenges of adherence. Multipurpose technologies (MPTs) – products designed to simultaneously protect against multiple sexual and reproductive health issues and potentially medications to treat or prevent other health conditions.
Intersection of HIV and Other Sexually Transmitted Infections (STIs) - prevention and treatment strategies to address interaction between HIV and STIs.

4. Immune-Based Prevention Trials Network – Responsible for the discovery and advancement of immune-based strategies to protect against HIV infection and associated infectious diseases, including TB and STIs, through Phase 1–3 clinical trials designed to answer key immunologic research questions to inform future candidate design, define correlates of protection, and identify safe and efficacious preventative regimens. Key aspects to this research agenda include:

Antibody-Mediated Prevention for HIV - design and conduct Phase 1–3 trials of passive immunization strategies.
Induced-Immunity for Prevention of HIV Acquisition - evaluate immunogens, immune modulators and adjuvants; and combinations of immunogens with antiretroviral drugs and other HIV prevention modalities. Conduct rapid, iterative "discovery medicine" trials to evaluate novel immunogens and adjuvants.
Analytical Treatment Interruption (ATI) Strategies - studies in PWH to evaluate viral control to inform HIV immune-based prevention approaches and immunotherapy development.
Immune-based Prevention Strategies Against Other HIV-associated Infectious Diseases - evaluate interventions against other infectious diseases (e.g., TB and STIs) and how these diseases may influence the safety and effectiveness of HIV prevention approaches.
Integration of Implementation and Behavioral Science Research - integration across all stages of immune-based product development and evaluation, assessing acceptability and mode of intervention.
Determinants of Immune Function and Intervention Effectiveness - evaluate how the microbiome, diet and environmental exposures share or alter immune function and the effectiveness of prevention interventions.

Other Research Areas: Each Network may have the opportunity to contribute to the research agenda for support of the development of strategies, interventions, and products for the rapid response against other/emerging infectious diseases (not listed above) of public health importance and to implement clinical trials in support of this agenda. The research agenda for those efforts will be developed post-award through cross-network, joint leadership efforts in conjunction with NIAID and other NIH staff.

Core and Protocol Funds Funding to carry out the network's research agenda falls into two categories:

Core Funds: initial fixed-base funding for infrastructure and salary support that is not protocol-specific. NIAID will provide core funds directly to the LOC, LC, SDMC and Network-affiliated CTUs on an annual basis.

Protocol Funds (PF): support to conduct protocols, including protocol-specific infrastructure or other requirements needed to conduct protocols at a clinical research site. PF varies annually, depending on costs of ongoing protocols. NIAID anticipates providing PF directly to the LOC, LC, SDMC and Network-affiliated CTUs on an annual basis.

The LOC will estimate PF needs for the network (salary and non-salary PF) based on communications with the LC, SDMC and CTUs/CRSs and submit an annual budget request to NIAID.

During the project period, additional protocol-specific (PS) sites may be added as needed to execute a specific protocol. These will be reviewed individually and, if approved, supported via a vendor agreement. These PS sites will be closed upon completion of the protocol.

Investigators proposing NIH-defined clinical trials may refer to the Research Methods Resources website for information about developing statistical methods and study designs.

See Section VIII. Other Information for award authorities and regulations.

Section II. Award Information

Funding Instrument

Cooperative Agreement: A financial assistance mechanism used when there will be substantial Federal scientific or programmatic involvement. Substantial involvement means that, after award, NIH scientific or program staff will assist, guide, coordinate, or participate in project activities. See Section VI.2 for additional information about the substantial involvement for this NOFO.

Application Types Allowed

New

Renewal - Renewals of RFA-AI-19-045

The OER Glossary and the How to Apply - Application Guide provide details on these application types. Only those application types listed here are allowed for this NOFO.

Clinical Trial?

Required: Only accepting applications that propose clinical trial(s).

Need help determining whether you are doing a clinical trial?

Funds Available and Anticipated Number of Awards

NIAID and partner components intend to commit an estimated total of $60 M to fund 45 - 65 awards in FY2028.

Award Budget

Application budgets are not limited but need to reflect the actual needs of the proposed project based on the size/scope of the CTU.

Award Project Period

The project period must be 7 years.

NIH grants policies as described in the NIH Grants Policy Statement will apply to the applications submitted and awards made from this NOFO.

Section III. Eligibility Information

1. Eligible Applicants

Eligible Organizations

Higher Education Institutions - Includes all types
Public/State Controlled Institutions of Higher Education
Private Institutions of Higher Education

Nonprofits Other Than Institutions of Higher Education

Nonprofits with 501(c)(3) IRS Status (Other than Institutions of Higher Education)
Nonprofits without 501(c)(3) IRS Status (Other than Institutions of Higher Education)

For-Profit Organizations

Small Businesses
For-Profit Organizations (Other than Small Businesses)

Local Governments

State Governments
County Governments
City or Township Governments
Special District Governments
Indian/Native American Tribal Governments (Federally Recognized)
Indian/Native American Tribal Governments (Other than Federally Recognized)

Federal Governments

Eligible Agencies of the Federal Government

U.S. Territory or Possession

Other

Independent School Districts

Public Housing Authorities/Indian Housing Authorities

Native American Tribal Organizations (other than Federally recognized tribal governments)

Faith-based or Community-based Organizations

Regional Organizations

Non-domestic (non-U.S.) Entities (Foreign Organizations)

Foreign Organizations/Foreign Collaborations

Non-domestic (non-U.S.) Entities (Foreign Organizations) are eligible to apply.

Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply.

Foreign components, as defined in the NIH Grants Policy Statement, are allowed.

NIH will no longer issue awards (i.e., new, renewal, or non-competing continuation) to domestic or foreign entities that involve foreign subawards/subcontracts. All NIH-funded research involving foreign subawards/subcontracts must be submitted in response to a NOFO that is specifically designated for funded international collaborations. See NIH Grants Policy Statement 16.8 Collaborative International Research Awards.

Applications involving foreign subawards/subcontracts submitted in response to this NOFO will be deemed noncompliant and will not be considered for funding. This policy applies to all monetary international collaborations resulting in foreign subawards/subcontracts, however, it does not preclude unfunded international collaborations or foreign components, funding for foreign consultants, or procurement of unique equipment or supplies from foreign vendors.

CRSs that are located outside of the United States (U.S.) must be part of the applicant institution (e.g., foreign off-site campus/facility of a domestic or foreign applicant institution and not foreign subawards). Each CRS may only be included in one CTU application.

Required Registrations

Applicant Organizations Applicant organizations must complete and maintain the following registrations as described in the How to Apply - Application Guide to be eligible to apply for or receive an award. All registrations must be completed prior to the application being submitted. Registration can take 6 weeks or more, so applicants should begin the registration process as soon as possible. Failure to complete registrations in advance of a due date is not a valid reason for a late submission, please reference NIH Grants Policy Statement Section 2.3.9.2 Electronically Submitted Applications for additional information System for Award Management (SAM) – Applicants must complete and maintain an active registration, which requires renewal at least annually. The renewal process may require as much time as the initial registration. SAM registration includes the assignment of a Commercial and Government Entity (CAGE) Code for domestic organizations which have not already been assigned a CAGE Code. Foreign organizations must obtain a NATO Commercial and Government Entity (NCAGE) Code (in lieu of a CAGE code) in order to register in SAM. Unique Entity Identifier (UEI)- A UEI is issued as part of the SAM.gov registration process. The same UEI must be used for all registrations, as well as on the grant application.

eRA Commons - Once the unique organization identifier is established, organizations can register with eRA Commons in tandem with completing their Grants.gov registrations; all registrations must be in place by time of submission. eRA Commons requires organizations to identify at least one Signing Official (SO) and at least one Program Director/Principal Investigator (PD/PI) account in order to submit an application.
Grants.gov – Applicants must have an active SAM registration in order to complete the Grants.gov registration.

Program Directors/Principal Investigators (PD(s)/PI(s)) All PD(s)/PI(s) must have an eRA Commons account. PD(s)/PI(s) should work with their organizational officials to either create a new account or to affiliate their existing account with the applicant organization in eRA Commons. Obtaining an eRA Commons account can take up to 2 weeks.

All PD(s)/PI(s) must be registered with ORCID. The personal profile associated with the PD(s)/PI(s) eRA Commons account must be linked to a valid ORCID ID. For more information on linking an ORCID ID to an eRA Commons personal profile see the ORCID topic in our eRA Commons online help.

Eligible Individuals (Program Director/Principal Investigator)

Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with their organization to develop an application for support.

For institutions/organizations proposing multiple PDs/PIs, visit the Multiple Program Director/Principal Investigator Policy and submission details in the Senior/Key Person Profile (Expanded) Component of the How to Apply - Application Guide.

2. Cost Sharing This NOFO does not require cost sharing as defined in the NIH Grants Policy Statement NIH Grants Policy Statement Section 1.2 Definition of Terms.

3. Additional Information on Eligibility Number of Applications

Applicant organizations may submit more than one application, provided that each application is scientifically distinct.

The NIH will not accept duplicate or highly overlapping applications under review at the same time, per NIH Grants Policy Statement Section 2.3.7.4 Submission of Resubmission Application. This means that the NIH will not accept:

A new (A0) application that is submitted before issuance of the summary statement from the review of an overlapping new (A0) or resubmission (A1) application.
A resubmission (A1) application that is submitted before issuance of the summary statement from the review of the previous new (A0) application.
An application that has substantial overlap with another application pending appeal of initial peer review (see NIH Grants Policy Statement 2.3.9.4 Similar, Essentially Identical, or Identical Applications).

Section IV. Application and Submission Information

1. Requesting an Application Package The application forms package specific to this opportunity must be accessed through ASSIST, Grants.gov Workspace or an institutional system-to-system solution. Links to apply using ASSIST or Grants.gov Workspace are available in Part 1 of this NOFO. See your administrative office for instructions if you plan to use an institutional system-to-system solution.

2. Content and Form of Application Submission It is critical that applicants follow the instructions in the Research (R) Instructions in the How to Apply - Application Guide except where instructed in this notice of funding opportunity to do otherwise (in this NOFO, in a policy notice, or other notice from NIH Guide for Grants and Contracts). Conformance to the requirements in the How to Apply - Application Guide is required and strictly enforced. Applications that are out of compliance with these instructions may be delayed or not accepted for review.

Page Limitations All page limitations described in the How to Apply – Application Guide and the Table of Page Limits must be followed, with the following additional instructions:

The Research Strategy must consist of the following sub-sections with the indicated page limits:

Sub-section A. Overview of the Clinical Trials Unit (CTU), one required - 30 pages Sub-section B. Administrative and Financial Resource Management, one required - 6 pages Sub-section C. Communication, one required - 6 pages Sub-section D. CTU Evaluation, one required - 6 pages Sub-section E. Clinical Research Site(s) (CRS), one required, maximum of eight - 30 pages each

Instructions for Application Submission

The following section supplements the instructions found in the How to Apply – Application Guide and should be used for preparing an application to this NOFO.

SF424(R&R) Cover All instructions in the How to Apply - Application Guide must be followed.

SF424(R&R) Project/Performance Site Locations

SF424(R&R) Other Project Information All instructions in the How to Apply - Application Guide must be followed, with the following additional instructions:

Facilities & Other Resources Provide the name and NIAID Clinical Research Management System [CRMS] site identification number (if applicable) for each proposed CRS (labeled CRS 1 through CRS 8).

Facility

Clinic location, infrastructure, layout, equipment, and security to support efficient clinical research operations
Specialized capabilities at each location
Information technology (IT) infrastructure, including hardware, connectivity, bandwidth, and data security
Capacity to effectively support implementation science research studies

Pharmacy

Pharmacy location, infrastructure, storage, security, and inventory systems
Compliance with quality standards as described in United States Pharmacopeial Convention (USP) Chapters or their equivalent (e.g., compliance with ISO class 5 environment standards, etc.)
Identification of CRS(s) that the pharmacy supports
Specialized equipment or capabilities

Laboratory

Location, infrastructure, storage, security, and specialized capabilities.
Testing capacity or supporting laboratory (if no local lab) for: chemistry, histology, toxicology, hematology, immunology (including CD4 and serology), virology (HIV viral load, DNA, resistance genotyping), metabolic tests, microbiology, pharmacology, cytology, specimen processing, tuberculosis (TB) testing, and urinalysis

Describe existing and planned relationships with organizations which demonstrate capacity to effectively conduct implementation science research studies.

Describe administrative and outside support or resources available to ensure adequate staffing and infrastructure.

SF424(R&R) Senior/Key Person Profile All instructions in the How to Apply - Application Guide must be followed, with the following additional instructions:

Provide clearly defined roles for CTU staff to ensure effective performance across the administrative, managerial, and scientific functions required to carry out Network Clinical Trials. Identify the following individuals as Senior/Key Personnel: CTU PD(s)/PI(s), CTU Coordinator, CRS Leader(s), CRS Coordinator(s), and Pharmacist(s) of Record.

Within the Common Forms for Biographical Sketch and NIH Biographical Sketch Supplement, provide the following information:

CTU PD(s)/PI(s): Describe relevant experience leading and managing a complex HIV/AIDS clinical research program, including specific roles and responsibilities. Highlight experience overseeing and managing IND-level protocols and implementation science research conducted across multiple Clinical Research Sites, including scientific leadership, strategic planning, prioritization, and resource allocation within a highly regulated research environment.
CTU Coordinator: Describe experience demonstrating strong administrative and financial management, training, staff supervision, evaluation, and operational logistics within a complex clinical research program operating in a highly regulated environment. Experience should align with the size and scope of the proposed CTU structure. Include experience ensuring and advancing compliance across multiple, complex, IND-level clinical research protocols and implementation science research.
CRS Leader (for each proposed CRS): Describe substantial experience managing and ensuring compliance across multiple, complex, IND-level HIV/AIDS clinical research protocols and implementation science research, including specific roles and responsibilities. Include experience in training, supervising and evaluating staff, and managing operational logistics appropriate to the size and scope of the proposed CRS.
CRS Coordinator (for each proposed CRS): Describe relevant experience implementing and managing complex, IND-level clinical research protocols and implementation science research, including specific roles and responsibilities.
Pharmacist(s) of Record (for each proposed CRS): Describe licensure and relevant experience providing pharmaceutical oversight and support for clinical research programs conducting IND-level protocols within a highly regulated environment, including specific roles and responsibilities.

R&R Budget All instructions in the How to Apply - Application Guide must be followed, with the following additional instructions:

Only request Core Funds for the initial fixed-base funding, infrastructure and salary support that is not protocol-specific (e.g., administrative and management support, community education and engagement structures and activities, clinical quality management activities, record retention).

Do not request Protocol Funds (PF) (e.g., protocol-specific personnel salary, participant recruitment and retention, protocol required tests and evaluations, participant reimbursement, community education and engagement structures and activities, and protocol specimen shipment and storage).

R&R Subaward Budget

PHS 398 Cover Page Supplement

PHS 398 Research Plan All instructions in the How to Apply - Application Guide must be followed, with the following additional instructions:

Research Strategy: The research strategy must consist of sub-sections A-E as designated below.

Sub-Section A: Overview of the Clinical Trials Unit (CTU)

Provide an organizational chart demonstrating an integrated approach to supporting the proposed HIV/AIDS Clinical Trials Network(s).
Describe how the proposed leadership structure and the leadership team's experience: (1) aligns with the proposed HIV/AIDS Networks, and (2) demonstrates the capacity to effectively manage a complex unit of the size and scope proposed.
Describe how the CTU is positioned to contribute to the proposed Network(s).
Briefly explain how the use of international sites will directly inform interventions or strategies to benefit Americans living with, or at risk for acquiring, HIV and other HIV-associated infections.
Describe lines of authority and staffing structure, including roles of CTU PD(s)/PI(s), CTU Coordinator, CRS Leader(s), CRS Coordinator(s), and Pharmacist(s) of Record.
Outline leadership structure and justification for aligning with the proposed NIH HIV/AIDS Clinical Trials Networks.
Without duplicating information provided in the Common Forms for Biographical Sketch and Current and Pending (Other) Support and NIH Biographical Sketch Supplement forms, summarize organizational leadership experience of the team over the past 5–7 years managing complex multicenter HIV/AIDS trials.
Describe strengths, challenges, and lessons learned from managing complex clinical trials in relevant participant populations, including implementation science research.
Describe the CTU's ability to effectively work within their regulatory environment, including maintaining compliance and keeping current with new regulations.
Describe processes for protocol selection including how decisions are made to allocate resources to support protocol implementation.
Describe proposed staff contribution to Network protocol teams and committees.
Describe how the CTU structure is cohesive, synergistic, and integrated, and how this integration is present within each of the elements and across the entire CTU.

For renewal applications, include Progress Reports in Sub-Section A.

Sub-section B. Administrative and Financial Resource Management

Outline financial management structure and staffing.
Describe strategies for optimizing productivity, cost containment measures, including shared infrastructure, if applicable.
Detail financial monitoring procedures, and plans for communicating resource allocation to CRS(s).

Sub-section C. Communication

Describe internal communication systems, including conflict resolution and decision dissemination.
Outline proposed communication with other Network elements (i.e., LOC, LC, SDMC).
Describe the process for communication with NIAID Division of AIDS (DAIDS) staff.
Detail processes for communicating study results to staff, participants, and communities.

Sub-section D. CTU Evaluation

Describe processes for assessing CRS readiness and compliance (e.g., U.S. Food and Drug Administration (FDA), International Council for Harmonisation (ICH)/Good Clinical Practice (GCP), NIAID, DAIDS, regulatory requirements).
Outline CRS preparation for protocol implementation.
Describe plans for evaluation and performance monitoring metrics, reporting frequency, and continuous improvement processes.
Define Clinical Research Site capacity thresholds and resource escalation procedures.
Outline close-out procedures for underperforming CTU elements.

Sub-section E. Clinical Research Sites (CRS) (minimum of 1, maximum of 8) Applications proposing more than 8 CRSs will be considered non-compliant and will not be reviewed.

For each CRS, provide an organizational chart and describe the following:

Staffing plan and team leadership experience overseeing IND-level multi-site clinical trials (past 5 – 7 years).
Previous experience conducting IND-level clinical trials (past 5 – 7 years), include study types, enrollment, retention, data quality, timelines). Identify previous challenges executing clinical trials and approaches to overcoming these challenges.
Overall quality management structure, including details about QC/QA processes, metrics, evaluation frequency, Corrective and Preventative Actions (CAPA) procedures, and continuous improvement processes.
Approaches to assessing, developing, delivering and evaluating training needs.
Mentoring and continuing education plans.
IRB and regulatory approval processes including timelines. Describe challenges and mitigation strategies.
Do not name additional Protocol-Specific (PS) Clinical Research Sites (sites that may be added during the project period to rapidly address emerging Clinical Trial Network clinical research protocol needs) in the application.

Research Agenda / Implementation Science Research Capacity

Describe and justify the proposed Network affiliation(s). Describe how coordination across Networks (if applicable) will be addressed, including strategies to ensure operational efficiencies.
Provide a description of existing and/or planned collaborations with partner organizations focused on implementation science research.
Describe experience conducting implementation science research in the past 5 – 7 years, including challenges and approaches to overcoming them.
Describe how the clinical experience of each CRS contributes to the conduct of complex clinical trials in relevant participant populations.
Describe previous experience of the CRSs with recruitment and retention of clinical trial participants within relevant participant populations.

Community Engagement

Describe Good Participatory Practice (GPP)-aligned community engagement and input plans along with organizational structure, including dedicated staff supporting community activities.
Define Community Advisory Board (CAB) roles, composition, elections, jurisdiction, and meeting frequency. Describe CRS-community relationships and outreach as well as CAB training and communication processes.
Describe how CAB activities will be evaluated and financial support allocated, as appropriate.

CRS Pharmacy

Describe the pharmacy structure, centralized activities (if any), and reporting lines (a diagram is recommended).
Provide a staffing plan, team experience, expertise and licensures/certifications, and integration of the Pharmacist(s) of Record into the CTU.
Outline oversight and communication processes.
Describe SOP development, pharmacy operations and study product management.
Outline pharmacy QC/QA activities, processes, procedures and regulatory compliance.

CRS Laboratory

Describe the laboratory structure, centralized functions, and integration into the CTU (diagram recommended).
Provide a staffing plan, certifications, and oversight processes.
Outline specimen management procedures to ensure proper specimen chain of custody, specimen tracking, local specimen storage capabilities, and specimen shipment processes.
Describe SOP development and regulatory compliance.
Describe material import/export challenges related to reliably maintaining test reagent inventories, equipment maintenance, and shipping study samples out of a country (if applicable).
Describe GCLP compliance across laboratories and associated clinics.

CRS Data Stewardship

Describe structure, reporting lines, and centralized functions.
Describe staffing, data quality assurance roles and coordination with the SDMC.
Detail data capture and eCRF procedures.
Describe IT infrastructure, data security, access controls, backup systems, and Electronic Health Records (EHR) access, if applicable, for NIAID monitoring contractors.

Letters of Support: Provide letters of support necessary to demonstrate the commitment of collaborators who have a significant role in the application. Do not submit letters of Network support.

Resource Sharing Plan: Individuals are required to comply with the instructions for the Resource Sharing Plans as provided in the How to Apply - Application Guide.

Other Plan(s):

All instructions in the How to Apply - Application Guide must be followed, with the following additional instructions:

A Data Management and Sharing Plan (DMS Plan) is required for any NIH-funded or conducted research that will generate scientific data. Applicants must submit the DMS Plan at the time of application using the NIH DMS Plan Format Page. The DMS Plan must address the elements in the structured format. Where the DMS Plan Format Page requires a "Yes or No" response, no additional narrative is allowed.

Appendix: Only limited Appendix materials are allowed. Follow all instructions for the Appendix as described in the How to Apply - Application Guide.

No publications or other material, with the exception of blank questionnaires or blank surveys, may be included in the Appendix.

PHS Human Subjects and Clinical Trials Information When involving human subjects research, clinical research, and/or NIH-defined clinical trials (and when applicable, clinical trials research experience) follow all instructions for the PHS Human Subjects and Clinical Trials Information form in the How to Apply - Application Guide, with the following additional instructions:

Other Requested Information For Renewal applications with ongoing clinical studies, applicants must include a list of all ongoing clinical studies and/or the unique ClinicalTrials.gov identifiers. All information must be combined in one single attachment using the filename "Ongoing Clinical Studies". If appropriate, please indicate for each study the NIAID Division of AIDS (DAIDS)-defined study status.

If you answered "Yes" to the question "Are Human Subjects Involved?" on the R&R Other Project Information form, you must include at least one human subjects study record using the Study Record: PHS Human Subjects and Clinical Trials Information form or Delayed Onset Study record.

Study Record: PHS Human Subjects and Clinical Trials Information All instructions in the How to Apply - Application Guide must be followed with the following additional instructions:

Although applicants must be prepared for clinical trials, definite plans for such involvement will not be possible at time of application. A Study Record MUST not be completed.

Delayed Onset Study Note: Delayed onset does NOT apply to a study that can be described but will not start immediately (i.e., delayed start). All instructions in the How to Apply - Application Guide must be followed, with the following additional instructions:

All Applications must add and complete the Delayed Onset Study record and must check box "Anticipated Clinical Trial?".

Study Title: use "Multiple Delayed-Onset Studies" Justification Attachment: Indicate that each clinical study protocol developed during the project period will be subject to approval through a procedure that involves an initial concept submission and subsequent review by the HIV/AIDS Clinical Trials Network and NIAID. If the concept receives approval, the next stage will be development of the protocol, which also must undergo review and approval prior to implementation through the HIV/AIDS Clinical Trials Network.

PHS Assignment Request Form

Foreign Organizations Foreign (non-U.S.) organizations must follow policies described in the NIH Grants Policy Statement, and procedures for foreign organizations described throughout the How to Apply Application Guide.

3. Unique Entity Identifier and System for Award Management (SAM) See Part 2. Section III.1 for information regarding the requirement for obtaining a unique entity identifier and for completing and maintaining active registrations in System for Award Management (SAM), NATO Commercial and Government Entity (NCAGE) Code (if applicable), eRA Commons, and Grants.gov

4. Submission Dates and Times Part I. contains information about Key Dates and times. Applicants are encouraged to submit applications before the due date to ensure they have time to make any application corrections that might be necessary for successful submission. When a submission date falls on a weekend or Federal holiday, the application deadline is automatically extended to the next business day.

Organizations must submit applications to Grants.gov (the online portal to find and apply for grants across all Federal agencies). Applicants must then complete the submission process by tracking the status of the application in the eRA Commons, NIH's electronic system for grants administration. NIH and Grants.gov systems check the application against many of the application instructions upon submission. Errors must be corrected and a changed/corrected application must be submitted to Grants.gov on or before the application due date and time. If a Changed/Corrected application is submitted after the deadline, the application will be considered late. Applications that miss the due date and time are subjected to the NIH Grants Policy Statement Section 2.3.9.2 Electronically Submitted Applications.

Applicants are responsible for viewing their application before the due date in the eRA Commons to ensure accurate and successful submission.

Information on the submission process and a definition of on-time submission are provided in the How to Apply – Application Guide.

5. Intergovernmental Review (E.O. 12372) This initiative is not subject to intergovernmental review.

6. Funding Restrictions All NIH awards are subject to the terms and conditions, cost principles, and other considerations described in the NIH Grants Policy Statement.

Pre-award costs are allowable only as described in the NIH Grants Policy Statement Section 7.9.1 Selected Items of Cost.

Awards issued under this notice of funding opportunity (NOFO) will be incrementally funded awards and may be issued for project periods of up to 7 years. Multi-year funded grants will not be allowed.
Grants awarded under this NOFO will not be provided the authority to automatically extend the final budget period one time to 12 months beyond the original project period end date shown in the Notice of Award. All extensions, including the first extension, will require prior approval. Please note a 7-year grant does not qualify for a no-cost extension.
Progress and financial reporting will be required and reviewed annually. All funds must be expended within the approved project period.

7. Other Submission Requirements and Information Applications must be submitted electronically following the instructions described in the How to Apply - Application Guide. Paper applications will not be accepted.

Applicants must complete all required registrations before the application due date. Section III. Eligibility Information contains information about registration.

For assistance with your electronic application or for more information on the electronic submission process, visit How to Apply – Application Guide. If you encounter a system issue beyond your control that threatens your ability to complete the submission process on-time, you must follow the Dealing with System Issues guidance. For assistance with application submission, contact the Application Submission Contacts in Section VII.

Important reminders:

All PD(s)/PI(s) must include their eRA Commons ID in the Credential field of the Senior/Key Person Profile form. Failure to register in the Commons and to include a valid PD/PI Commons ID in the credential field will prevent the successful submission of an electronic application to NIH. See Section III of this NOFO for information on registration requirements.

The applicant organization must ensure that the unique entity identifier provided on the application is the same identifier used in the organization's profile in the eRA Commons and for the System for Award Management. Additional information may be found in the How to Apply - Application Guide.

See more tips for avoiding common errors.

Upon receipt, applications will be evaluated for completeness and compliance with application instructions by the Center for Scientific Review and responsiveness by components of participating organizations, NIH. Applications that are incomplete, non-compliant and/or nonresponsive will not be reviewed.

Mandatory Disclosure

Recipients or subrecipients must submit any information related to violations of federal criminal law involving fraud, bribery, or gratuity violations potentially affecting the federal award. See Mandatory Disclosures, 2 CFR 200.113 and NIH Grants Policy Statement Section 4.1.36.

Send written disclosures to the NIH Chief Grants Management Officer listed on the Notice of Award for the IC that funded the award and to the HHS Office of Inspector Grant Self Disclosure Program at grantdisclosures@oig.hhs.gov.

Post Submission Materials Applicants are required to follow the instructions for post-submission materials, as described in the policy

Section V. Application Review Information

1. Criteria Only the review criteria described below will be considered in the review process. Applications submitted to the NIH in support of the NIH mission are evaluated for scientific and technical merit through the NIH peer review system.

A proposed Clinical Trial application may include study design, methods, and intervention that are not by themselves innovative but address important questions or unmet needs. Additionally, the results of the clinical trial may indicate that further clinical development of the intervention is unwarranted or lead to new avenues of scientific investigation.

Overall Impact

Reviewers will provide an overall impact score to reflect their assessment of the likelihood for the project to exert a sustained, powerful influence on the research…

This is the start of the file's text. The full file is on GovTribe.

Other files

File Type Posted
PKG00294603.pdf PDF
RFA-AI-28-004-Full-Announcement.html HTML file

On GovTribe

Work with this file

  • Download the original file
  • Contacts named in this file
  • Similar government files
  • Ask GovTribe AI about this file

File details come from the government source that posted it. Updated .